In vitro effect of human recombinant growth hormone on lymphocyte and granulocyte function of healthy and uremic children.
The recombinant human growth hormone (rhGH), currently used in supraphysiological doses to promote growth acceleration in chronic renal failure children (CRF), also has the ability to influence their impaired immune functions. The effect of human growth hormone on the lymphoproliferative response in vitro was analyzed in the peripheral blood lymphocytes of 25 healthy and 11 uremic children. In 72% of the uremic cases and in 60% of the healthy individual children the hormone increased the lymphoproliferation alone, and/or when used in combination with phytohaemagglutinine. The range of the effective hormone concentrations differed individually. Using semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) a great variation in the gene expression of growth hormone- (GH)-receptor in peripheral lymphocytes was detected. The respiratory burst activity of peripheral polymorphonuclear leukocytes (PMN) in vitro, in response to GH alone and when combined with suboptimal dose of phorbolester (PMA), was assessed by measuring luminol enhanced chemiluminescence in ten uremic and 18 healthy children. In six out of the ten of the CRF patients and in eight out of 18 of the healthy children the GH enhanced the oxidative burst activity of granulocytes provoked by a suboptimal dose of PMA. However, the effective doses (10, 50 and 300 ng/ml) and incubation times (0, 45 and 90 min) showed individual variations. Our data suggest that rhGH treatment in uremic children could be advantageous considering this population's enhanced susceptibility to bacterial, viral and fungal infections.
Department of Genetics, Cellular- and Immunobiology, Semmelweis Medical University, Budapest, Hungary.
B
B
Derfalvi
K
K
Nemet
C
C
Szalai
E
E
Kenesei
P
P
Sallay
T
T
Tulassay
A
A
Falus
D000293:Adolescent; D002648:Child; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D018507:Gene Expression Regulation, Developmental / Q000235:genetics; D006098:Granulocytes / Q000187:drug effects*; D019382:Human Growth Hormone / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007107:Immune System / Q000187:drug effects / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D008214:Lymphocytes / Q000187:drug effects*; D008297:Male; D019798:Neopterin / Q000097:blood; D009504:Neutrophils / Q000187:drug effects; D016133:Polymerase Chain Reaction; D011986:Receptors, Somatotropin / Q000235:genetics; D016897:Respiratory Burst / Q000187:drug effects; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; D019798:Neopterin; D013755:Tetradecanoylphorbol Acetate